Export financials
Nevro Corp. (NVRO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Nevro Corp. Cash Flow 2024-2011 | NVRO
Brief cash flow overview of Nevro Corp.
Cash flows are assessed across five available annual periods spanning 2020 to 2024.
Operating cash flow is negative at -$19.4 million, leaving internal funding capacity weak.
Operating cash flow was positive in only 2 of five periods. Cash generation remains unstable.
Cash from operations as a share of revenue fell from 0.3% to -4.8%, weakening cash efficiency.
What the cash flows show
Taken together, Nevro Corp.'s cash flow indicators point to increased dependence on reserves or outside financing.
Annual Cash Flow Nevro Corp.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-19.4 M | -58.8 M | 24.7 M | -41.9 M | 1.19 M | -50.2 M | -5.71 M | -14.3 M | -58.5 M | - | - | - | - | - |
Depreciation & Amortization |
7.95 M | 6.8 M | 6.18 M | 4.9 M | 4.79 M | 4.56 M | 3.89 M | 2.51 M | 1.72 M | 614 K | 96 K | 47 K | 39 K | - |
Accounts Payables |
24.5 M | 22.5 M | 26.8 M | 32 M | 23.1 M | 16 M | 23.5 M | 18.5 M | 16.2 M | 21.9 M | 4.46 M | - | - | - |
Accounts Receivables |
71.9 M | 79.4 M | 78.9 M | 70.5 M | 77.7 M | 82.8 M | 80.7 M | 67.3 M | 52.8 M | 22.5 M | 6.61 M | - | - | - |
Total Inventories |
103 M | 119 M | 99.6 M | 93.5 M | 83.3 M | 91.6 M | 92 M | 98.1 M | 85.2 M | 62.4 M | 14.9 M | - | - | - |
All numbers in USD currency
Quarterly Cash Flow Nevro Corp.
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-38 M | -40.8 M | -32.7 M | - | -49.9 M | -43.8 M | -29.3 M | - | 38.1 M | -41.3 M | -28.4 M | - | -26.7 M | -11.4 M | -6.87 M | - | -10.7 M | -22 M | -5.18 M | - | -36.8 M | -33.4 M | -21.7 M | - | -10.7 M | -5.11 M | -5.7 M | - | -14.3 M | -14.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
1.91 M | 2.01 M | 2.05 M | - | 1.72 M | 1.67 M | 1.54 M | - | 1.6 M | 1.56 M | 1.5 M | - | 1.22 M | 1.15 M | 1.1 M | - | 1.17 M | 1.18 M | 1.3 M | - | 1.11 M | 1.11 M | 1.08 M | - | 1.08 M | 952 K | 815 K | - | 666 K | 623 K | 485 K | - | 465 K | 389 K | 380 K | - | 157 K | 84 K | 46 K | - | 26 K | 23 K | 16 K | - | 9 K | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
20.3 M | 22.9 M | 21.2 M | 22.5 M | 28.9 M | 30.3 M | 29.2 M | 26.8 M | 31.8 M | 31.3 M | 27.1 M | 32 M | 32.8 M | 31 M | 29.1 M | 23.1 M | 24.5 M | 18.7 M | 19.9 M | 16 M | 19.8 M | 23.2 M | 23.1 M | 23.5 M | 20.2 M | 23.5 M | 22.2 M | 18.5 M | 17.8 M | 11 M | 12.1 M | 16.2 M | 13.1 M | 13.1 M | 11.8 M | 21.9 M | 12.9 M | 7.26 M | 8.15 M | 4.46 M | 3.5 M | 4.46 M | 4.46 M | 3.18 M | 3.18 M | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
70.6 M | 74.3 M | 76.9 M | 79.4 M | 69 M | 69.4 M | 65.7 M | 78.9 M | 69.6 M | 66.9 M | 63.1 M | 70.5 M | 63.5 M | 65.4 M | 66.1 M | 77.7 M | 78.7 M | 56.7 M | 64.7 M | 82.8 M | 70.8 M | 67.1 M | 69 M | 80.7 M | 74 M | 66 M | 62.7 M | 67.3 M | 53.4 M | 53.6 M | 50.8 M | 52.8 M | 40.8 M | 36.9 M | 29 M | 22.5 M | 10.5 M | 7.59 M | 7.31 M | 6.61 M | 5.68 M | 6.61 M | 6.61 M | 6.6 M | 6.6 M | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
120 M | 126 M | 121 M | 119 M | 122 M | 120 M | 113 M | 99.6 M | 98.5 M | 93.5 M | 90.6 M | 93.5 M | 91.8 M | 85.7 M | 85.8 M | 83.3 M | 84.1 M | 91.8 M | 93 M | 91.6 M | 90.7 M | 92.4 M | 93.1 M | 92 M | 93.6 M | 95 M | 97.5 M | 98.1 M | 95.6 M | 87 M | 84.7 M | 85.2 M | 73.4 M | 68.1 M | 67.6 M | 62.4 M | 42.7 M | 26.4 M | 18.2 M | 14.9 M | 12.1 M | 14.9 M | 14.9 M | 10.1 M | 10.1 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Nevro Corp., reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
AxoGen
AXGN
|
$ 43.32 | 0.04 % | $ 1.99 B | ||
|
Bruker Corporation
BRKR
|
$ 59.67 | 0.18 % | $ 9.06 B | ||
|
Cognyte Software Ltd.
CGNT
|
$ 8.73 | 1.16 % | $ 637 M | ||
|
ClearPoint Neuro
CLPT
|
$ 14.97 | 13.03 % | $ 424 M | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
CONMED Corporation
CNMD
|
$ 45.8 | 3.31 % | $ 1.42 B | ||
|
Cytosorbents Corporation
CTSO
|
$ 4.91 | 0.75 % | $ 306 M | ||
|
Delcath Systems
DCTH
|
$ 15.96 | 1.8 % | $ 572 M | ||
|
Eargo
EAR
|
- | - | $ 10.2 M | ||
|
AdaptHealth Corp.
AHCO
|
$ 5.7 | 0.43 % | $ 770 M | ||
|
Electromed
ELMD
|
$ 27.57 | 0.11 % | $ 228 M | ||
|
Establishment Labs Holdings
ESTA
|
$ 67.76 | 3.69 % | $ 2.01 B | ||
|
Edwards Lifesciences Corporation
EW
|
$ 86.82 | 0.51 % | $ 50.8 B | ||
|
Align Technology
ALGN
|
$ 148.17 | 4.36 % | $ 10.7 B | ||
|
Helius Medical Technologies
HSDT
|
$ 2.88 | 2.45 % | $ 63.5 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
$ 15.53 | 2.76 % | $ 1.19 B | ||
|
Inogen
INGN
|
$ 5.09 | 2.55 % | $ 135 M | ||
|
Inspire Medical Systems
INSP
|
$ 69.06 | 0.57 % | $ 2.03 B | ||
|
IRIDEX Corporation
IRIX
|
$ 0.63 | 0.08 % | $ 10.7 M | ||
|
IRadimed Corporation
IRMD
|
$ 86.35 | 0.08 % | $ 1.1 B | ||
|
Integer Holdings Corporation
ITGR
|
$ 126.32 | 0.02 % | $ 4.39 B | ||
|
LENSAR
LNSR
|
$ 7.15 | 0.14 % | $ 85.5 M | ||
|
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | ||
|
Apyx Medical Corporation
APYX
|
$ 2.95 | 1.37 % | $ 121 M | ||
|
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | ||
|
Medtronic PLC
MDT
|
$ 89.3 | 0.08 % | $ 114 B | ||
|
MiMedx Group
MDXG
|
$ 4.77 | 0.2 % | $ 705 M | ||
|
Accuray Incorporated
ARAY
|
$ 0.23 | 1.0 % | $ 28.2 M | ||
|
Myomo
MYO
|
$ 1.64 | 0.3 % | $ 68.6 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 0.7 | 0.45 % | $ 45.4 M | ||
|
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M | ||
|
InspireMD
NSPR
|
$ 0.74 | 0.16 % | $ 47.6 M | ||
|
Orthofix Medical
OFIX
|
$ 9.18 | 2.23 % | $ 364 M | ||
|
Outset Medical
OM
|
$ 3.09 | 5.45 % | $ 47 K | ||
|
Boston Scientific Corporation
BSX
|
$ 44.62 | 0.31 % | $ 66.1 B | ||
|
Insulet Corporation
PODD
|
$ 136.49 | 0.01 % | $ 9.6 B | ||
|
Profound Medical Corp.
PROF
|
$ 5.74 | 0.16 % | $ 174 M | ||
|
Quanterix Corporation
QTRX
|
$ 3.16 | 4.93 % | $ 135 M | ||
|
AVITA Medical
RCEL
|
$ 10.95 | 0.61 % | $ 305 M | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
Sintx Technologies
SINT
|
$ 1.78 | 3.98 % | $ 4.94 M | ||
|
Smith & Nephew plc
SNN
|
$ 26.82 | 0.07 % | $ 23.3 B | ||
|
Inari Medical
NARI
|
- | - | $ 4.23 B | ||
|
Sensus Healthcare
SRTS
|
$ 3.03 | 0.32 % | $ 49.5 M | ||
|
Stryker Corporation
SYK
|
$ 273.4 | 0.38 % | $ 104 B | ||
|
Tactile Systems Technology
TCMD
|
$ 22.43 | 0.55 % | $ 513 M | ||
|
TELA Bio
TELA
|
$ 1.3 | 0.71 % | $ 61 M | ||
|
Viemed Healthcare
VMD
|
$ 8.8 | 1.24 % | $ 342 M | ||
|
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.05 % | $ 764 M | ||
|
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M |